Skip to content

Section archive

Chemotherapy

In a trial of more than 700 advanced lung cancer patients, adding Tarceva to Avastin delayed cancer progression to 4.8 months from 3.7, at the cost of more rash, diarrhea, hypertension and fatigue and eight deaths from adverse events. Continuing Alimta extended survival to 13.4 months from 10.6.

1 min read

2 stories